BioPharma Pharma Research

New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL

ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual ...

 November 18, 2022 | News

Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the approval of the Investigational New Drug (IND) application by China National Medical Prod...

 November 17, 2022 | News

Standigm Synthetic Research Center successfully accelerates drug discovery in its first year

Standigm, the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Center's first year. In the last 12 mont...

 November 17, 2022 | News

Simcere and Idorsia enter into a licensing agreement for daridorexant in China

Jinsheng Ren,Chairman and CEO of Simcere commented: "This licensing agreement represents an important and exciting step in pursuing Simcere's mission of p...

 November 16, 2022 | News

Daewoong and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectiv...

 November 14, 2022 | News

Smith+Nephew Academy Singapore opens, bringing medical education and digital innovation to healthcare professionals across Asia-Pacific

Supporting Smith+Nephew's purpose of Life Unlimited, the S+N Academy Singapore offers an engaging, immersive and interactive training environment for healt...

 November 10, 2022 | News

Monash University Implements Antibody Discovery Application by Utilizing the Berkeley Lights Beacon® Platform

The technology is housed in the Monash Antibody Technology Facility (MATF) where researchers not only from Monash University but elsewhere in Victoria...

 November 10, 2022 | News

Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion

Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research col...

 November 09, 2022 | News

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidne...

 November 04, 2022 | News

NCCN Working with Medlive to Advance High-Quality Cancer Care in China and Worldwide

The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is announc...

 November 03, 2022 | News

I Peace partners with the California Institute for Regenerative Medicine [CIRM]

 I Peace has been providing GMP Induced Pluripotent Stem Cells (iPSC) for a variety of cell therapy developers and pharmaceutical companies in the pas...

 November 02, 2022 | News

OSF HealthCare and Bradley University formalize partnership to solve pressing health care problems

Designed to create a robust, collaborative research community, the new agreement is between employees at two of Peoria's largest and most impactf...

 October 31, 2022 | News

Ardigen supports JUMP-CP Consortium to transform drug discovery with Cell Painting technology

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cel...

 October 28, 2022 | News

Merck Highlights New Data for Evobrutinib

Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining lo...

 October 26, 2022 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close